NUCEIVA

This brand name is authorized in Austria, Canada, Croatia, Estonia, Ireland, Italy, Lithuania, Poland.

Active ingredients

The drug NUCEIVA contains one active pharmaceutical ingredient (API):

1	PrabotulinumtoxinA UNII 0A6JH35GMQ - PRABOTULINUMTOXIN A
	Botulinum toxin type A is a protein complex derived from Clostridium botulinum. The protein consists of type A neurotoxin and several other proteins. Under physiological conditions it is presumed that the complex dissociates and releases the pure neurotoxin. Intramuscular injection of the neurotoxin complex blocks cholinergic transport at the neuromuscular junction by preventing the release of acetylcholine. The nerve endings of the neuromuscular junction no longer respond to nerve impulses and secretion of the chemotransmitter is prevented (chemical denervation).
	Read more about Botulinum toxin type A

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
NUCEIVA Powder for solution for injection	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
M03AX01	Botulinum toxin	M Musculo-skeletal system → M03 Muscle relaxants → M03A Muscle relaxants, peripherally acting agents → M03AX Other muscle relaxants, peripherally acting agents
Discover more medicines within M03AX01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
CA	Health Products and Food Branch	02480158
EE	Ravimiamet	1802450, 1836884
IT	Agenzia del Farmaco	048254015, 048254027
LT	Valstybinė vaistų kontrolės tarnyba	1088577, 1091756
PL	Rejestru Produktów Leczniczych	100428290, 100461031